Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PostbiotiX Slowing
- Development stage
- Unknown
- Lead developer
- Postbiotica
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PostbiotiX Slowing is a postbiotic food supplement developed by Postbiotica to address intestinal disorders, specifically those involving irregular transit and diarrhea. It utilizes the proprietary PBTech® fermentation technology to produce its primary active ingredient, fermented fructooligosaccharides (FOS) derived from *Lactobacillus paracasei* CNCM I-5220. This postbiotic component is designed to rebalance the intestinal microbiota and restore mucosal barrier function. The formulation is enhanced with mallow (*Malva sylvestris*), which aids in regulating stool volume and consistency, and chamomile (*Matricaria chamomilla*), which supports gastrointestinal motility and gas elimination. It is intended for oral administration and is suitable for both adults and children over 3 years of age.
- Brand names
- PostbiotiX Slowing
- Other names
- Slowing
Beyond the preview
Go deeper on PostbiotiX Slowing.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PostbiotiX Slowing.